Opportunity Information: Apply for PAR 10 001
Apply for PAR 10 001
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Drug Discovery for Nervous System Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.866 Aging Research.
- This funding opportunity was created on Oct 2, 2009 and posted on Oct 2, 2009.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Special district governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) State governments Independent school districts Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) County governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Drug Discovery for Nervous System Disorders (R01) funding opportunity (PAR-10-001) is an NIH discretionary grant program designed to push new therapeutic ideas toward real, testable drug candidates for diseases of the nervous system. The core aim is to support projects focused on discovering and carrying out preclinical testing of novel compounds that could prevent or treat neurological and other nervous system-related disorders. In practical terms, the opportunity is geared toward research teams that are ready to move beyond basic observations and into a structured drug discovery pipeline, including identifying promising molecules and generating the early non-clinical evidence needed to justify further development.
This FOA uses the NIH Research Project Grant (R01) mechanism, which generally supports more mature, hypothesis-driven projects with a clearer development plan and defined milestones than smaller exploratory mechanisms. NIH notes that this announcement runs in parallel with a companion FOA (PAR-10-002) that has the same scientific scope but uses the R21 Exploratory/Development mechanism, which is typically intended for earlier-stage, higher-risk concepts or preliminary work. Applicants whose projects are more established, with strong rationale and feasibility for compound discovery and preclinical testing, would generally be aiming at the R01 version.
Funding levels are not guaranteed and depend on federal appropriations and NIH institute priorities, and awards are specifically described as contingent on both the availability of funds and the receipt of enough high-quality, meritorious applications. The listing includes an award ceiling of $250,000, indicating the program anticipated projects within that cap (applicants would still be expected to follow NIH budget rules and the specific instructions in the full announcement). The opportunity did not require cost sharing or matching funds, which is common for NIH research project grants and helps reduce barriers for academic and nonprofit applicants.
Eligibility is broad and includes many organization types across the public, private, academic, and nonprofit spectrum. Eligible applicants include public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, for-profit organizations (including small businesses), state and local governments (including county and city or township governments), special district governments, independent school districts, public housing authorities, and tribal governments and tribal organizations. The eligibility language also explicitly includes a wide range of mission-driven and capacity-building institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, and U.S. territories or possessions. It also allows non-U.S. entities (foreign organizations) and certain regional organizations, indicating NIH’s willingness to fund strong science wherever it can be appropriately administered under NIH policies.
From an administrative standpoint, the opportunity was posted and created on October 2, 2009, and the original and final closing date listed is January 7, 2013, with an archive date of February 7, 2013. The responsible agency is the National Institutes of Health, and the program is associated with multiple CFDA numbers that reflect NIH’s involvement across mental health, alcohol research, drug abuse and addiction, neuroscience and neurological disorders, and aging research (93.242, 93.273, 93.279, 93.853, 93.866). That mix signals that the FOA was relevant to a wide set of NIH institutes and centers that fund nervous system disorder research, spanning psychiatric, neurological, substance use, and age-related conditions.
Overall, this FOA was essentially a preclinical drug discovery and development push for nervous system disorders under a full R01 research project structure: identify or design novel compounds, test and optimize them using appropriate preclinical methods, and build a strong evidence package that could support later translational steps. The full announcement, application instructions, and any scientific or administrative nuances were provided through the NIH Grants Guide link associated with PAR-10-001, with NIH’s Office of Extramural Research webmaster listed as the contact for access or linking issues.
Frequently Asked Questions (FAQs)
What is the Drug Discovery for Nervous System Disorders (R01) opportunity (PAR-10-001)?
PAR-10-001 is an NIH discretionary funding opportunity that supports drug discovery and preclinical testing projects aimed at developing new therapeutic ideas into real, testable drug candidates for diseases of the nervous system.
What is the main goal of this FOA?
The core aim is to fund projects that discover novel compounds and carry out preclinical testing to generate early non-clinical evidence that could justify further therapeutic development for neurological and other nervous system-related disorders.
What types of activities does this program emphasize?
This opportunity is geared toward teams moving beyond basic observations into a structured drug discovery pipeline, including identifying promising molecules and producing preclinical (non-clinical) data to support later development steps.
What NIH grant mechanism is used?
This FOA uses the NIH Research Project Grant (R01) mechanism, which generally supports more mature, hypothesis-driven projects with a clearer development plan and defined milestones.
How is this R01 FOA different from the companion R21 FOA (PAR-10-002)?
NIH describes PAR-10-001 (R01) as running in parallel with PAR-10-002 (R21), which has the same scientific scope but uses the R21 Exploratory/Development mechanism. The R21 is typically intended for earlier-stage, higher-risk concepts or preliminary work, while the R01 is more appropriate for projects that are more established with stronger feasibility and a clearer development plan for compound discovery and preclinical testing.
Who is this funding opportunity intended for?
It is intended for research teams that are ready to pursue a structured drug discovery and preclinical testing effort for nervous system disorders, with sufficient rationale and feasibility to fit an R01-level project.
What kinds of diseases or conditions are in scope?
The FOA targets diseases and disorders of the nervous system. The associated NIH program areas span mental health, alcohol research, drug abuse and addiction, neuroscience and neurological disorders, and aging research, indicating relevance to a wide range of nervous system-related conditions.
What is the award amount for this program?
The listing includes an award ceiling of $250,000, indicating projects were anticipated within that cap. Applicants are expected to follow NIH budget rules and the specific instructions in the full announcement.
Is funding guaranteed if an application is submitted?
No. Funding levels are not guaranteed and depend on federal appropriations and NIH institute priorities. Awards are described as contingent on the availability of funds and the receipt of sufficient high-quality, meritorious applications.
Is cost sharing or matching required?
No. The opportunity did not require cost sharing or matching funds.
What organizations are eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (including small businesses), and multiple levels and types of government entities.
Are state, local, or special district governments eligible?
Yes. Eligible applicants include state governments, local governments (including county and city or township governments), and special district governments.
Are independent school districts eligible?
Yes. Independent school districts are explicitly included among eligible applicants.
Are public housing authorities eligible?
Yes. Public housing authorities are listed as eligible applicants.
Are tribal governments and tribal organizations eligible?
Yes. Tribal governments and tribal organizations are included in the eligibility language.
Are mission-driven institutions like HBCUs, HSIs, and TCCUs eligible?
Yes. The eligibility language explicitly includes institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs), along with Alaska Native and Native Hawaiian Serving Institutions.
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly included as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly included in the eligibility language.
Can non-U.S. (foreign) organizations apply?
Yes. The eligibility language allows non-U.S. entities (foreign organizations) and certain regional organizations, reflecting NIH’s willingness to fund strong science under NIH policies.
Which federal agency runs this opportunity?
The responsible agency is the National Institutes of Health (NIH).
What are the key dates for this FOA?
The opportunity was posted and created on October 2, 2009. The original and final closing date listed is January 7, 2013. The archive date is February 7, 2013.
Is this opportunity still open?
Based on the provided dates (final closing date of January 7, 2013 and archive date of February 7, 2013), it is not open.
Which CFDA numbers are associated with this FOA?
The program is associated with multiple CFDA numbers: 93.242, 93.273, 93.279, 93.853, and 93.866.
What do the CFDA numbers suggest about the scope of NIH involvement?
The mix of CFDA numbers indicates the FOA was relevant across multiple NIH areas, including mental health, alcohol research, drug abuse and addiction, neuroscience and neurological disorders, and aging research.
Where were full instructions and application details provided?
The full announcement, application instructions, and scientific/administrative details were provided through the NIH Grants Guide link associated with PAR-10-001.
Who is listed as a contact for access or linking issues?
NIH’s Office of Extramural Research webmaster is listed as the contact for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: NHLBI Clinical Trial Pilot Studies (R34)
Previous opportunity: Drug Discovery for Nervous System Disorders (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 10 011 Funding Number: PA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 10 013 Funding Number: PA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 10 002 Funding Number: RFA CA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) Apply for RFA CA 10 003 Funding Number: RFA CA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 10 005 Funding Number: RFA CA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) Apply for RFA CA 10 004 Funding Number: RFA CA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Drug Abuse Dissertation Research Epidemiology, Prevention, Treatment, Services, and/or Women and Sex/Gender Differences (R36) Apply for PAR 10 020 Funding Number: PAR 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| AIDS Science Track Award for Research Transition (R03) Apply for PAR 10 021 Funding Number: PAR 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| State and Community Tobacco Control Policy and Media Research (U01) Apply for RFA CA 10 008 Funding Number: RFA CA 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effectiveness Research on Smoking Cessation in Hospitalized Patients (U01) Apply for RFA HL 10 020 Funding Number: RFA HL 10 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R01) Apply for PA 10 025 Funding Number: PA 10 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21) Apply for PA 10 026 Funding Number: PA 10 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (Phased Innovation Award R21/R33) Apply for PAR 10 024 Funding Number: PAR 10 024 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 10 023 Funding Number: PA 10 023 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.